EMC China Lab

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices

Views :
Update time : 2025-03-01

With the implementation of ISO 10993-1:2018, most devices that have prolonged contact with the human body (>30 days) now require an evaluation of chronic toxicity and carcinogenicity as part of their biological risk assessment. In Table A.1 (iso 10993-1:2018), these biological endpoints are marked with an "E", indicating that they must be evaluated during risk assessment. This evaluation can be conducted using existing data, additional endpoint-specific tests, or a justified rationale explaining why additional data are unnecessary. The inclusion of these biological evaluation endpoints has also drawn regulatory attention, with review feedback requiring further refinement of chronic toxicity and carcinogenicity assessments based on Table A.1.

 

Evaluation of Chronic Toxicity and Carcinogenicity of Medical Devices(图1)


Chronic Toxicity Test (Project Duration: ~8–14 months)

Chronic toxicity is a systemic toxicity study conducted by repeated or continuous exposure to the test sample throughout a significant portion of the animal's lifespan to observe any adverse effects. Animals should be continuously exposed for 6–12 months. When using rodents (rats, mice) for single-dose group studies, each group should include at least 30 animals (15 per sex). The evaluation of repeated exposure studies is based on body weight, clinical observations, hematology, clinical biochemistry, gross pathology, histopathology, and other test indicators.

 

Carcinogenicity Test (Project Duration: ~32–34 months)

The purpose of the carcinogenicity test is to assess tumor development in test animals during or after exposure to different doses of the test material through appropriate routes, covering major life stages of the animals.

 

- If an extract-based test is used, a standalone carcinogenicity study can be conducted according to OECD TG 451, or a combined chronic toxicity and carcinogenicity study can be conducted following OECD TG 453 to comprehensively evaluate both biological endpoints while considering the possibility of solid-state carcinogenicity.

- When evaluating the carcinogenicity of a medical device using a single animal species, the selection and justification should follow ISO 10993-2.

- For rodents, each group should include at least 50 animals per sex, with the study typically lasting 24 months to cover most of the animal’s lifespan.

 

Evaluation criteria include body weight, clinical observations, tumor formation and progression, hematology, gross pathology, histopathology, and other test indicators. Although transgenic animals can be used for carcinogenicity tests, their application in medical device evaluations has not yet been established.

 

Alternatives to Animal Testing for Chronic Toxicity and Carcinogenicity Evaluations

Both chronic toxicity and carcinogenicity studies involve long-term animal testing, posing significant financial and time challenges for product development. So, is animal testing always necessary for evaluating these biological endpoints?

 

According to iso 10993-18 (Material Chemical Characterization) and ISO 10993-17 (Toxicological Risk Assessment), toxicological evaluations based on material characterization can be used for assessing systemic toxicity endpoints, including:

 

- Systemic toxicity (acute, subacute, subchronic, and chronic toxicity)

- Genotoxicity

- Reproductive toxicity

- Carcinogenicity

 

Therefore, when determining whether to conduct chronic toxicity and carcinogenicity studies, it is essential to first consider the intended use and classification of the device to identify whether these biological endpoints require evaluation.

 

Manufacturers should leverage existing product information as much as possible, including raw materials, manufacturing processes, preclinical and clinical data (if available). When additional studies are necessary to support risk assessment, a tiered approach is recommended:

 

1. Prioritize chemical and physical characterization

2. Perform in vitro screening tests

3. Review characterization and in vitro test results before proceeding with animal testing

4. Justify the necessity of long-term animal studies

 

By following this approach, the biological risk assessment can be conducted in a scientifically rational and efficient manner.


Email:hello@jjrlab.com


Leave Your Message


Write your message here and send it to us


Related News
Read More >>
How to get an ASTM F2549 Test Report? How to get an ASTM F2549 Test Report?
11 .20.2026
Get your ASTM F2549 test report for frame child carriers at JJR Lab. Our ISO/IEC 17025, CMA & CN...
What Is ASTM F2907 Compliance Certification? What Is ASTM F2907 Compliance Certification?
11 .20.2026
Get ASTM F2907 compliance certification for sling carriers at JJR Lab. Our ISO/IEC 17025, CMA & ...
How to get an ASTM F2907 Test Report? How to get an ASTM F2907 Test Report?
11 .19.2026
Get your ASTM F2907 test report for Amazon baby sling CPC compliance at JJR LAB. Our ISO/IEC 17025, ...
How to get an ASTM F2050 Test Report? How to get an ASTM F2050 Test Report?
11 .19.2026
Get your ASTM F2050 test report for infant carriers at JJR Lab. Our ISO/IEC 17025, CMA & CNAS ac...
How to get an EN 12227 Test Report? How to get an EN 12227 Test Report?
11 .18.2026
Ensure your EN 12227:2010 children‘s playpen complies with EU safety standards. JJR Laboratory offer...
What is the Amazon EN 12227 Standard What is the Amazon EN 12227 Standard
11 .17.2026
Children‘s playpens selling on Amazon Europe in 2027 must meet EN 12227. JJR Lab, an ISO/IEC 17025 a...
Amazon Japan & Australia Battery-Powered Produ Amazon Japan & Australia Battery-Powered Produ
11 .16.2026
Ensure Amazon Japan/Australia compliance for battery-powered products. JJR LAB (CMA/CNAS/ISO/IEC 170...
What is Textile 16 CFR 303 Certification Complianc What is Textile 16 CFR 303 Certification Complianc
11 .13.2026
Ensure US apparel market entry with Textile 16 CFR 303 compliance. JJR Lab offers ISO/IEC 17025, CMA...

Leave Your Message